NovoCure Ltd (NVCR): Next-Year EPS Estimate 26.52%
As of 2026-06-04, NovoCure Ltd (NVCR) has a next-year EPS growth estimate of 26.52%.
On 2026-05-04, analyst consensus for NVCR's next-year EPS growth shifted from 27.94% to 26.52% — a negative change of 1.42 percentage points. The revised estimate has been sustained across 24 subsequent trading sessions. Current-year growth is projected at -30.68%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Medical Devices
- EPS growth next year
- 26.52%
- EPS growth this year
- -30.68%
- EPS next quarter (est)
- -$0.33
- Last price
- $17.99
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 26.52% | -30.68% | -$0.33 | $17.99 |
| 2026-06-03 | 26.52% | -30.68% | -$0.33 | $16.15 |
| 2026-06-02 | 26.52% | -30.68% | -$0.33 | $15.82 |
| 2026-06-01 | 26.52% | -30.68% | -$0.33 | $16.56 |
| 2026-05-31 | 26.52% | -30.68% | -$0.33 | $17.04 |
| 2026-05-28 | 26.52% | -30.68% | -$0.33 | $17.25 |
| 2026-05-27 | 26.52% | -30.68% | -$0.33 | $16.99 |
| 2026-05-26 | 26.52% | -30.68% | -$0.33 | $18.26 |
| 2026-05-25 | 26.52% | -30.68% | -$0.33 | $17.96 |
| 2026-05-24 | 26.52% | -30.68% | -$0.33 | $17.96 |
| 2026-05-21 | 26.52% | -30.68% | -$0.33 | $17.90 |
| 2026-05-20 | 26.52% | -30.68% | -$0.33 | $17.75 |
| 2026-05-19 | 26.52% | -30.68% | -$0.33 | $17.01 |
| 2026-05-18 | 26.52% | -30.68% | -$0.33 | $17.46 |
| 2026-05-17 | 26.52% | -30.68% | -$0.33 | $17.58 |
| 2026-05-14 | 26.52% | -30.68% | -$0.33 | $18.05 |
| 2026-05-13 | 26.52% | -30.68% | -$0.33 | $18.34 |
| 2026-05-12 | 26.52% | -30.68% | -$0.33 | $18.31 |
| 2026-05-11 | 26.52% | -30.68% | -$0.33 | $18.10 |
| 2026-05-10 | 26.52% | -30.68% | -$0.33 | $17.89 |
| 2026-05-07 | 26.52% | -30.68% | -$0.33 | $16.83 |
| 2026-05-06 | 26.52% | -30.68% | -$0.33 | $16.50 |
| 2026-05-05 | 26.52% | -30.68% | -$0.33 | $15.88 |
| 2026-05-04 | 26.52% | -30.68% | -$0.33 | $16.93 |
| 2026-05-03 | 27.94% | -31.62% | -$0.34 | $16.62 |
| 2026-04-30 | 27.97% | -31.62% | -$0.34 | $15.21 |
Recent News
- Two Medical Stocks Skyrocket After Demolishing Views - And One Is About To Break OutInvestor's Business Daily
- NovoCure: Q1 Earnings SnapshotAssociated Press
- Novocure Reports First Quarter 2026 Financial ResultsBusiness Wire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is NovoCure Ltd's next-year EPS growth estimate?▾
As of 2026-06-04, NovoCure Ltd (NVCR) has a next-year EPS growth estimate of 26.52%, based on analyst consensus.
When was the latest EPS estimate revision for NVCR?▾
The most recent revision occurred on 2026-05-04, when analysts adjusted the next-year EPS growth estimate from 27.94% to 26.52%.
What sector and industry does NovoCure Ltd belong to?▾
NovoCure Ltd operates in the Healthcare sector, specifically the Medical Devices industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. NVCR appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. NovoCure Ltd (NVCR) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports